Finance

Lists
Why is QNCX up 8,07%?
Dive Deeper
QNCX:NASDAQ
Quince Therapeutics Inc
USD 31,73
+8,07%
(+2,37) 1D
9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QNCX...
Open
USD 30,50
High
USD 37,00
Low
USD 29,84
Mkt. cap
32,27 m
Avg. vol.
22,66 k
Volume
138,62 k
52-wk high
USD 909,98
52-wk low
USD 15,10
EPS
-USD 125,71
Beta
1,33
Shares outstanding
1,02 m
No. of employees
38
Open
USD 30,50
High
USD 37,00
Low
USD 29,84
Mkt. cap
32,27 m
Avg. vol.
22,66 k
Volume
138,62 k
52-wk high
USD 909,98
52-wk low
USD 15,10
EPS
-USD 125,71
Beta
1,33
Shares outstanding
1,02 m
No. of employees
38
News stories
From web sources and news partners
About Quince Therapeutics Inc
CEO-
Employees38
Founded2012
HeadquartersSouth San Francisco, Kalifornië, Verenigde State van Amerika
Sector-
Websitequincetx.com
Analyst ratings
Based on 8 analysts giving stock ratings to QNCX in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for QNCX in the last 3 months.
Highest
Current USD 31,73
USD 98,00 (+208,86%)
Average
USD 75,63 (+138,35%)
Lowest
USD 68,00 (+114,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
USD 72,00
+126,9%
10/09/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
USD 98,00
+208,9%
09/30/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
USD 68,00
+114,3%
09/29/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
USD 68,00
+114,3%
09/30/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
USD 70,00
+120,6%
09/24/2026
Jonathan Wolleben
Citizens JMP
Buy
Upgraded
USD 77,00
+142,7%
09/22/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Reiterated
USD 70,00
+120,6%
08/17/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
USD 82,00
+158,4%
08/17/2026
Jason McCarthy
Maxim Group
Hold
Downgraded
-
-
02/02/2026
Elemer Piros
Lucid Capital
Sell
Downgraded
-
-
01/30/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
01/30/2026
Last report
14 Aug. 2026
Fiscal period
Q2 2026
-USD 12,15 / -USD 12,39
+1,88%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,08 m
12,60 m
6,84 m
5,46 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,28 m
3,64 m
4,27 m
16,63 m
Operating expense
11,36 m
16,24 m
11,11 m
22,09 m
Total operating expenses
11,36 m
16,24 m
11,11 m
22,09 m
Operating income
-11,36 m
-16,24 m
-11,11 m
-22,09 m
Other non operating income
191,00 k
-17,12 m
32,84 m
3,78 m
EBT including unusual items
-13,49 m
-36,31 m
30,57 m
-75,41 m
EBT excluding unusual items
-10,87 m
-32,65 m
21,88 m
-17,72 m
Income tax expense
-46,00 k
3,15 m
-5,34 m
75,00 k
Effective tax rate
0,34%
-8,66%
-17,46%
-0,10%
Other operating expenses
-
-
-
-
Net income
-13,44 m
-39,46 m
35,91 m
-75,49 m
Net profit margin
-
-
-
-
Earnings per share
-50,00
-152,00
57,60
-12,15
Interest and investment income
300,00 k
227,00 k
160,00 k
584,00 k
Interest expense
-
-
-
-
Net interest expenses
300,00 k
227,00 k
160,00 k
584,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-11,33 m
-16,20 m
-11,08 m
-22,05 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme